Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children’s Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children’s Research Hospital.
Type
Public
HQ
Seattle, US
Size (employees)
533 (est)+43%
Juno Therapeutics is headquartered in Seattle, US

Key People at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO
Stan Riddell

Stan Riddell

Scientific Co-Founder
Isabelle Rivière

Isabelle Rivière

Scientific co-founder
Phil Greenberg

Phil Greenberg

Scientific Co-Founder
Renier Brentjens

Renier Brentjens

Scientific Co-Founder

Juno Therapeutics Office Locations

Juno Therapeutics has offices in Seattle, Washington, Bothell, Waltham and in 2 other locations
Seattle, US (HQ)
300 307 Westlake Ave N

Juno Therapeutics Metrics

Juno Therapeutics Financial Metrics

Revenue (2016)

$79.4 m

Revenue growth (2015-16), %

336%

Net income (2016)

($245.6 m)

Market capitalization (28-Apr-2017)

$2.6 b

Closing share price (28-Apr-2017)

$24.9

Cash (31-Dec-2016)

$187.9 m
Juno Therapeutics's current market capitalization is $2.6 b.
Juno Therapeutics's revenue was reported to be $79.4 m in FY, 2016 which is a 336% increase from the previous period.
FY, 2015FY, 2016

Revenue

$18.2 m$79.4 m

Revenue growth, %

336%

R&D expense

$46.2 m$264.3 m

General and administrative expense

$4.2 m$70.7 m

Operating expense total

$51.7 m$335 m

EBIT

($51.7 m)($255.6 m)

EBIT margin, %

(284%)(322%)

Pre tax profit

($51.8 m)($256.2 m)

Income tax expense

$2.8 m$10.7 m

Net Income

($51.8 m)($245.6 m)
FY, 2015FY, 2016

Cash

$252.4 m$187.9 m

Current Assets

$951.8 m$772.3 m

PP&E

$42.1 m$81.7 m

Goodwill

$122.1 m$221.3 m

Total Assets

$1.4 b$1.3 b

Accounts Payable

$4.1 m

Current Liabilities

$119.7 m$114.9 m

Additional Paid-in Capital

$1.7 b$1.9 b

Retained Earnings

($585.7 m)($831.2 m)

Total Equity

$1.1 b$1.1 b

Financial Leverage

1.3 x1.3 x
FY, 2015FY, 2016

Net Income

($51.8 m)($245.6 m)

Depreciation and Amortization

$2 k$14.2 m

Accounts Payable

($2.7 m)$3.7 m

Cash From Operating Activities

($103.6 m)($189.8 m)

Purchases of PP&E

($42 k)($56.2 m)

Cash From Investing Activities

($42 k)$88.6 m

Cash From Financing Activities

$66.5 m$36.8 m

Juno Therapeutics Market Value History

Juno Therapeutics Job Categories

Juno Therapeutics Online Presence

Juno Therapeutics News

Juno Therapeutics Company Life

You may also be interested in